Cargando…

Treatment of idiopathic membranous nephropathy in adults: KDIGO 2012, cyclophosphamide and cyclosporine A are out, rituximab is the new normal

The 2012 Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guidelines for glomerulonephritis shed light on the complex world of glomerulonephritis therapy. However, they may no longer apply to idiopathic membranous nephropathy, as recently concluded by the KDIGO 2019 Working Group....

Descripción completa

Detalles Bibliográficos
Autores principales:	Rojas-Rivera, Jorge Enrique, Carriazo, Sol, Ortiz, Alberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Glomerulonephritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6768298/ https://www.ncbi.nlm.nih.gov/pubmed/31583088 http://dx.doi.org/10.1093/ckj/sfz127

Ejemplares similares

Rituximab-induced serum sickness in the treatment of idiopathic membranous nephropathy
por: Cheong, Jamie, et al.
Publicado: (2018)

Treatment pattern in patients with idiopathic membranous nephropathy—practices in Sweden at the start of the millennium
por: Lönnbro-Widgren, Jennie, et al.
Publicado: (2016)

Idiopathic membranous nephropathy in patients with diabetes mellitus: a diagnostic and therapeutic quandary!
por: Bhadauria, Dharmendra, et al.
Publicado: (2018)

The investigative burden of membranous nephropathy in the UK
por: Hamilton, Patrick, et al.
Publicado: (2019)

IgA nephropathy in Greece: data from the registry of the Hellenic Society of Nephrology
por: Stangou, Maria, et al.
Publicado: (2018)

Anti-phospholipase A2 receptor antibody and spontaneous remission in membranous nephropathy
por: Diaz, Montserrat, et al.
Publicado: (2018)

Necrotizing and crescentic glomerulonephritis with membranous nephropathy in a patient exposed to levamisole-adulterated cocaine
por: Carrara, Camillo, et al.
Publicado: (2016)

MicroRNAs: a new avenue to understand, investigate and treat immunoglobulin A nephropathy?
por: Selvaskandan, Haresh, et al.
Publicado: (2018)

Comparing outcomes of biopsy-proven anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis patients treated with cyclophosphamide in the 20th and 21st centuries: a 23-year study
por: Whatmough, Steven, et al.
Publicado: (2018)

Study protocol: responding to the needs of patients with IgA nephropathy, a social media approach
por: Graham-Brown, Matthew P M, et al.
Publicado: (2018)

Antiphospholipase 2 receptor antibody levels to predict complete spontaneous remission in primary membranous nephropathy
por: Rodas, Lida M, et al.
Publicado: (2018)

Azithromycin suppressed relapses of idiopathic nephrotic syndrome in a child
por: Hara, Hiromichi, et al.
Publicado: (2018)

Membranous nephropathy due to chronic mercury poisoning from traditional Indian medicines: report of five cases
por: Doshi, Manan, et al.
Publicado: (2018)

Efficacy of mycophenolate treatment in adults with steroid-dependent/frequently relapsing idiopathic nephrotic syndrome
por: Sandoval, Diego, et al.
Publicado: (2017)

Higher serum galactose-deficient immunoglobulin A1 concentration is associated with stronger mesangial cellular inflammatory response and more severe histologic findings in immunoglobulin A nephropathy
por: Nguyen, Celine, et al.
Publicado: (2018)

Therapeutic variability in adult minimal change disease and focal segmental glomerulosclerosis
por: Fernandez-Juarez, Gema, et al.
Publicado: (2016)

Post-streptococcal glomerulonephritis associated with atypical hemolytic uremic syndrome: to treat or not to treat with eculizumab?
por: Kakajiwala, Aadil, et al.
Publicado: (2016)

Rapidly progressive glomerulonephritis due to coexistent anti-glomerular basement membrane disease and fibrillary glomerulonephritis
por: Cheungpasitporn, Wisit, et al.
Publicado: (2016)

Clinical factors influencing the decision to transfuse after percutaneous native kidney biopsy
por: Whittier, William L., et al.
Publicado: (2016)

Minimal change disease onset observed after bevacizumab administration
por: Hanna, Ramy M., et al.
Publicado: (2016)

Atypical anti-glomerular basement membrane disease
por: Troxell, Megan L., et al.
Publicado: (2016)

Post-infectious glomerulonephritis with crescents in adults: a retrospective study
por: Baikunje, Shashidhar, et al.
Publicado: (2016)

Membranoproliferative glomerulonephritis and C3 glomerulopathy in children: change in treatment modality? A report of a case series
por: Spartà, Giuseppina, et al.
Publicado: (2018)

Revisiting post-infectious glomerulonephritis in the emerging era of C3 glomerulopathy
por: Khalighi, Mazdak A., et al.
Publicado: (2016)

Efficacy and safety of adrenocorticotropic hormone treatment in glomerular diseases: a systematic review and meta-analysis
por: Kittanamongkolchai, Wonngarm, et al.
Publicado: (2016)

Minimal change disease and malaria
por: Rangwani, Neil, et al.
Publicado: (2018)

Continuous B-cell depletion in frequently relapsing, steroid-dependent and steroid-resistant nephrotic syndrome
por: Cortazar, Frank B, et al.
Publicado: (2018)

Atypical anti-glomerular basement membrane disease presenting as macroscopic haematuria, loin pain and acute kidney injury after intensive exercise
por: Le Flecher, Arnaud, et al.
Publicado: (2019)

From KDIGO 2012 towards KDIGO 2021 in idiopathic membranous nephropathy guidelines: what has changed over the last 10 years?
por: Stai, Stamatia, et al.
Publicado: (2022)

Recurrent focal segmental glomerulosclerosis apparently resistant to plasmapheresis improves after surgical repair of arteriovenous fistula aneurysms
por: Ding, Yanli, et al.
Publicado: (2016)

Kidney transplant outcomes in familial C3 glomerulopathy
por: Wong, Limy, et al.
Publicado: (2016)

WCN23-0542 SARS-COV2 ASSOCIATED MINIMAL CHANGE GLOMERULONEPHRITIS LONG-TERM EFFECTS
por: Akl, A.I., et al.
Publicado: (2023)

Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series
por: Cortazar, Frank B., et al.
Publicado: (2017)

Treatment with rituximab in idiopathic membranous nephropathy
por: Fiorentino, Marco, et al.
Publicado: (2016)

Membranous Nephropathy: Pilot Study of a Novel Regimen Combining Cyclosporine and Rituximab
por: Waldman, Meryl, et al.
Publicado: (2016)

Therapeutic effects of rituximab combined with cyclophosphamide on refractory idiopathic thrombocytopenic purpura
por: Wang, Jiuhe, et al.
Publicado: (2019)

Cyclophosphamide induced early remission and was superior to rituximab in idiopathic membranous nephropathy patients with high anti-PLA2R antibody levels
por: Xue, Cheng, et al.
Publicado: (2023)

Hypertensive nephropathy: a major roadblock hindering the advance of precision nephrology
por: Carriazo, Sol, et al.
Publicado: (2020)

Two cases of idiopathic membranous nephropathy treated with rituximab
por: Young Yoon, Jae, et al.
Publicado: (2013)

Effectiveness and safety of cyclophosphamide or tacrolimus therapy for idiopathic membranous nephropathy
por: Zou, Honghong, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_081a90je961gq44sq3an9uon4t